Ayahuasca and Depression — What 60+ Studies Are Actually Showing

When we started holding retreats a decade ago, the research base on Ayahuasca for depression was a handful of small studies and a lot of indigenous testimony. As of late 2025, there are more than 60 peer-reviewed studies — including randomized controlled trials, brain imaging studies, and long-term follow-ups. The picture is more nuanced than either the cheerleaders or the skeptics will tell you. Here is the careful version.

The headline finding

In treatment-resistant depression — meaning depression that has not responded adequately to two or more conventional antidepressants — a single Ayahuasca session has produced rapid and clinically significant reductions in depression severity in multiple controlled studies. The 2019 Brazilian RCT (Palhano-Fontes et al., Psychological Medicine) showed: 64% of treatment-resistant depressed participants who received Ayahuasca had a clinical response (more than 50% reduction in depression scores) at one week post-session, compared to 27% on placebo. Effects persisted for at least 21 days post-session, the duration of the formal study window. Subsequent observational studies have followed people out to 6 and 12 months.

What the research suggests is happening neurologically

BDNF and neuroplasticity

Ayahuasca dramatically increases brain-derived neurotrophic factor (BDNF) — a protein critical for neuroplasticity, the brain's ability to form new connections. Depressed brains characteristically have low BDNF and reduced plasticity in the prefrontal cortex and hippocampus. SSRIs slowly increase BDNF over weeks to months. Ayahuasca appears to do this within 24 hours. BDNF elevation has been documented across multiple independent studies (de Almeida et al. 2019, Galvão-Coelho et al. 2020).

Default Mode Network suppression

Functional MRI studies (Palhano-Fontes 2015, Sanches 2016) show that Ayahuasca temporarily suppresses the Default Mode Network — the brain network associated with self-referential thinking, mind-wandering, and rumination. Depressed brains have characteristically over-active DMN; the rumination loop is one of the experiential signatures of major depression. The temporary 'quieting' of this network during Ayahuasca, and the apparent re-setting of its baseline activity afterward, may explain why people emerge from a single ceremony feeling 'unstuck.'

Serotonin receptor activity

DMT and harmaline are both serotonin-system active. Specifically, they bind to 5-HT2A receptors (the same receptor implicated in psilocybin's antidepressant effects) and modulate 5-HT1A and 5-HT2C. The combination produces a different signaling pattern than SSRIs — which is part of why Ayahuasca seems to work in cases where SSRIs have not.

Inflammation and the gut-brain axis

Newer research (2022 onwards) is exploring Ayahuasca's effect on inflammatory markers — depression is increasingly understood as having an inflammatory component. Preliminary data suggest Ayahuasca reduces several inflammatory cytokines in depressed participants, with effects persisting weeks. Whether this is mechanistic or downstream of the experience is still being researched.

What the research does NOT support

• Ayahuasca is not a 'cure' for depression. The studies show response and remission rates that are clinically meaningful but not universal.
• A single session is not enough for everyone. Some participants relapse over 3–6 months. Whether multi-session protocols extend the benefit is still under study.
• Ayahuasca is not safe to combine with most antidepressants. The drug interaction risk (serotonin syndrome) is real and well-documented. See our SSRI tapering article.
• Ayahuasca does not work as well in major depression with psychotic features, severe bipolar disorder, or active suicidality. These conditions are exclusion criteria in nearly every clinical study and in our screening.
• The 'set and setting' matter as much as the molecule. The same dose in a clinical hospital room produces different outcomes than the same dose in a traditional ceremony with proper preparation. Most of the research has happened in clinical settings; we believe — and have observed — that traditional ceremony amplifies the therapeutic effect.

Treatment-resistant depression specifically

If you have treatment-resistant depression — defined as failing two or more antidepressant trials at adequate dose and duration — the research supports Ayahuasca as a reasonable option to consider, *under specific conditions*:

• Adequate medical and psychiatric screening before participating
• Proper tapering off any current antidepressant medications, with prescriber supervision
• Traditional ceremonial setting with experienced practitioners (the research effects do not transfer to recreational use)
• Concurrent psychotherapy — ideally trauma-informed — for at least 6 months around the experience
• Realistic expectations: a 60% chance of meaningful improvement is excellent for treatment-resistant cases, but it is not 100%, and it is not permanent without ongoing work

Specific subtypes of depression

Depression with childhood-trauma background

Ayahuasca seems particularly effective when depression is rooted in early-life trauma. The combination of memory access, emotional reprocessing, and self-compassion that Ayahuasca tends to facilitate aligns well with how trauma-driven depression seems to release. We see this clearly in our circle.

Grief-related depression

The research is thinner here, but observational data and our clinical experience suggest Ayahuasca is genuinely helpful for prolonged grief and complicated bereavement. The medicine often facilitates a form of 'completion' with the deceased that talk therapy alone struggles to reach.

Existential / meaning-related depression

Mid-life depression characterized by 'I have everything I should want and feel nothing' often responds well. The medicine reframes the relationship between self and life in a way that is hard to describe but consistently reported.

Atypical and hormonal depression

Less studied. Anecdotal evidence is mixed. Recommend additional caution and conventional treatment continuation.

Bipolar depression

We do not work with active bipolar disorder. The risk of triggering mania or hypomania is real and the research is clear that this is a contraindicated population.

What integration looks like with depression specifically

If you come to Ayahuasca with depression, the integration window is more critical than for someone who came for general personal work. Our recommendations:

• A standing therapy session with a trauma-informed therapist for at least 12 weeks afterward
• A medication management plan with your prescriber covering both pre-retreat tapering and post-retreat decisions
• A mood-tracking practice — daily journal or an app — to catch any return of symptoms early
• A specific plan for the 'test moment' when symptoms try to return (usually weeks 2–4)
• Possibly a second ceremony 4–6 months out to reinforce the work

What you should know before deciding

Ayahuasca is a serious tool that is genuinely helping a lot of people whose depression had not budged for years. It is also not a one-shot magic bullet, not safe with most current medications, and not a substitute for ongoing therapeutic care. If you have treatment-resistant depression and a stable enough situation to taper your medication safely with your prescriber and to take 10 days for a real retreat plus 90 days of careful integration, the research supports the path. If your situation is more fragile than that, the research equally supports continuing your conventional care while you build the foundation for a future session.

The honest middle ground we hold most often: Ayahuasca is not for everyone with depression, but it is for many. Talk to your prescriber. Talk to us. We will tell you honestly what we think before you book.

Selected references

For deeper reading, look up: Palhano-Fontes et al. (2019), Psychological Medicine; Osório et al. (2015), Brazilian Journal of Psychiatry; Sanches et al. (2016), Journal of Clinical Psychopharmacology; de Almeida et al. (2019), Frontiers in Psychology; Galvão-Coelho et al. (2020), Psychopharmacology. The Multidisciplinary Association for Psychedelic Studies (MAPS) and the Beckley Foundation maintain ongoing literature reviews.

◦ the molecule is interesting ◦ what you do with the opening is everything ◦